Natco Pharma Ltd

Natco Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Natco Pharma Ltd

₹ 620 -2.15%
30 May - close price
natcopharma.co.in BSE: 524816 NSE : NATCOPHARM
About

NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. [1]
NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.[2]

Key Points

Exports of formulations - Complex Generics (49% of sales)[1]
The company is focused on niche opportunities in the US
In FY22, Completed acquisition of Dash Pharmaceuticals LLC to build a frontend presence in the US [2]
Focus on Para IV and First-to-File molecules
Started winning tenders in Asian markets including Malaysia and Thailand

Company is focused on high-barrier-to-entry products that are typically characterized by one or more of the following: Intricate Chemistry, Challenging delivery systems, Difficult or complex manufacturing process

Website BSE NSE
  • Market Cap ₹ 11,309 Cr.
  • Current Price ₹ 620
  • High / Low ₹ 779 / 502
  • Stock P/E 15.8
  • Book Value ₹ 267
  • Dividend Yield 0.89 %
  • ROCE 18.0 %
  • ROE 15.7 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has been maintaining a healthy dividend payout of 28.0%

Cons

  • The company has delivered a poor sales growth of 4.38% over past five years.
  • Company has a low return on equity of 9.99% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
455 563 802 355 331 410 377 560 597 885 432 492 898
326 392 526 273 255 300 307 459 615 489 337 387 559
Operating Profit 128 171 276 82 76 110 70 102 -19 395 95 106 339
OPM % 28% 30% 34% 23% 23% 27% 19% 18% -3% 45% 22% 22% 38%
22 19 26 31 28 17 38 30 14 34 20 21 29
Interest 4 4 3 3 4 2 4 5 7 4 4 4 3
Depreciation 30 28 29 30 30 34 35 36 38 40 42 42 41
Profit before tax 117 158 271 80 71 91 70 91 -50 386 70 81 324
Tax % 20% 23% 25% 21% 25% 18% 7% 12% -2% 17% 19% 23% 15%
Net Profit 93 122 204 63 53 75 65 80 -50 320 57 62 276
EPS in Rs 5.17 6.74 11.11 3.44 2.91 4.11 3.57 4.41 -2.77 17.55 3.11 3.41 15.11
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
524 661 739 825 1,042 2,020 2,185 2,094 1,915 2,052 1,945 2,707
414 511 560 615 777 1,337 1,256 1,300 1,332 1,446 1,681 1,772
Operating Profit 109 150 179 210 266 683 928 795 583 606 264 936
OPM % 21% 23% 24% 25% 25% 34% 42% 38% 30% 30% 14% 35%
9 1 17 0 12 14 40 130 107 104 99 105
Interest 23 26 37 32 23 18 15 19 22 13 18 14
Depreciation 16 22 30 47 51 54 66 81 100 117 143 164
Profit before tax 80 102 129 132 204 624 887 825 569 580 202 862
Tax % 26% 36% 24% 1% 24% 22% 22% 22% 19% 24% 16% 17%
Net Profit 58 66 98 130 156 485 695 642 458 442 170 715
EPS in Rs 3.83 4.58 6.21 8.10 9.02 27.88 37.74 35.24 25.31 24.18 9.31 39.18
Dividend Payout % 16% 17% 16% 12% 14% 24% 22% 18% 27% 22% 48% 14%
Compounded Sales Growth
10 Years: 15%
5 Years: 4%
3 Years: 12%
TTM: 39%
Compounded Profit Growth
10 Years: 26%
5 Years: 1%
3 Years: 17%
TTM: 421%
Stock Price CAGR
10 Years: 22%
5 Years: -5%
3 Years: 2%
1 Year: -7%
Return on Equity
10 Years: 15%
5 Years: 12%
3 Years: 10%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
31 31 33 33 35 35 37 36 36 36 36 36
Reserves 442 502 693 813 1,261 1,614 3,035 3,452 3,737 4,085 4,227 4,837
259 338 240 312 113 222 173 386 316 268 416 167
173 209 229 226 413 446 470 428 498 403 430 617
Total Liabilities 905 1,080 1,196 1,384 1,822 2,318 3,715 4,303 4,588 4,792 5,109 5,657
320 583 645 710 710 833 1,019 1,227 1,584 2,023 2,312 2,427
CWIP 164 106 124 129 212 336 480 638 518 223 130 64
Investments 63 2 2 2 22 32 76 169 112 304 308 392
359 389 425 543 878 1,116 2,140 2,270 2,373 2,242 2,360 2,774
Total Assets 905 1,080 1,196 1,384 1,822 2,318 3,715 4,303 4,588 4,792 5,109 5,657

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
65 61 144 93 112 346 464 669 417 299 46
-125 -111 -108 -120 -176 -299 -1,116 -611 -175 -107 4
63 26 -35 29 154 -48 651 -51 -251 -186 35
Net Cash Flow 3 -24 0 2 90 -1 -2 7 -8 6 85

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 66 72 59 85 92 86 106 88 105 73 116 115
Inventory Days 198 220 283 331 482 213 389 545 534 570 496 432
Days Payable 166 159 172 189 372 160 239 224 244 104 105 153
Cash Conversion Cycle 98 132 170 228 202 138 257 410 395 539 507 394
Working Capital Days 54 67 71 99 131 111 244 275 355 294 335 261
ROCE % 16% 17% 18% 17% 18% 39% 35% 23% 14% 13% 4% 18%

Shareholding Pattern

Numbers in percentages

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
48.93 48.91 48.91 48.87 48.87 48.87 48.86 48.81 48.80 48.80 48.82 48.84
20.40 19.32 18.17 16.35 13.73 12.53 12.26 11.94 11.65 11.67 11.73 11.91
12.82 13.71 15.04 16.14 16.21 17.78 18.08 16.15 15.30 14.30 14.93 15.38
17.85 18.07 17.88 18.65 21.19 20.82 20.80 23.10 24.25 25.23 24.53 23.87

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls